Neumora Shows Promise with New Alzheimer's Agitation Treatment

Neumora Therapeutics (NMRA) announces positive Phase 1b results for NMRA-511, a new drug candidate showing clinically meaningful improvements in Alzheimer's disease agitation symptoms with favorable safety profile.